Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
The present invention provides methods for treating an individual having solid or lymphatic tumor comprising locally administering to the site of the tumor an oncolytic virus, and systemically administering an immunomodulator (including a combination of immunomodulators). The methods may further comprise local administration to the site of the tumor a second immunomodulator (including a combination of immunomodulators). Also provided are compositions and kits for the cancer therapy methods.
1. A method of treating a solid or lymphatic tumor in an individual, comprising: a) intravesically administering an effective amount of an oncolytic virus, wherein the oncolytic virus is CG0070; and b) intravenously administering an effective amount of an immunomodulator, wherein the immunomodulator is pembrolizumab, and wherein the solid or lymphatic tumor is bladder cancer.
2. The method of claim 1 , further comprising locally administering to the site of the tumor a pretreatment composition prior to the administration of the oncolytic virus.
3. The method of claim 2 , wherein the pretreatment composition comprises a transduction enhancing agent.
4. The method of claim 1 , wherein the individual is subject to a prior therapy prior to the administration of the oncolytic virus and the immunomodulator.
5. The method of claim 4 , wherein the prior therapy comprises administration of a therapeutic agent.
6. The method of claim 4 , wherein the prior therapy is provided at a dose that is insufficient to treat the tumor.
7. The method of claim 4 , wherein the prior therapy is treatment with Bacillus Calmette-Guerin (BCG).
8. The method of claim 4 , wherein the individual is resistant to the prior therapy.
9. The method of claim 4 , wherein the individual has recurrent bladder cancer after the prior therapy.
10. The method of claim 1 , wherein the bladder cancer is non-muscle invasive bladder cancer.
11. The method of claim 10 , wherein the non-muscle invasive bladder cancer comprises carcinoma in situ.
12. The method of claim 11 , wherein the non-muscle invasive bladder cancer further comprises Ta, T1, or a combination thereof.
13. The method of claim 7 , wherein:
a. the individual is resistant to treatment of bladder cancer with BCG;
b. the individual is initially responsive to treatment of bladder cancer with BCG but has progressed after treatment; or
c. the individual has recurrent bladder cancer after treatment with BCG.
14. The method of claim 1 , wherein the oncolytic virus is administered weekly for 6 weeks.
15. The method of claim 1 , wherein the immunomodulator is administered once every 6 weeks.
16. The method of claim 3 , wherein the transduction enhancing agent is N-Dodecyl-β-D-maltoside (DDM).
17. The method of claim 1 , wherein the method comprises intravenous administration of a single immunomodulator.